Titre
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Mocroft, A.
Auteure/Auteur
Miro, J.M.
Auteure/Auteur
Wandeler, G.
Auteure/Auteur
Llibre, J.M.
Auteure/Auteur
Boyd, A.
Auteure/Auteur
van Bremen, K.
Auteure/Auteur
Beniowski, M.
Auteure/Auteur
Mikhalik, J.
Auteure/Auteur
Cavassini, M.
Auteure/Auteur
Maltez, F.
Auteure/Auteur
Duvivier, C.
Auteure/Auteur
Uberti Foppa, C.
Auteure/Auteur
Knysz, B.
Auteure/Auteur
Bakowska, E.
Auteure/Auteur
Kuzovatova, E.
Auteure/Auteur
Domingo, P.
Auteure/Auteur
Zagalo, A.
Auteure/Auteur
Viard, J.P.
Auteure/Auteur
Degen, O.
Auteure/Auteur
Milinkovic, A.
Auteure/Auteur
Benfield, T.
Auteure/Auteur
Peters, L.
Auteure/Auteur
Contributrices/contributeurs
Harxhi, A.
Losso, M.
Kundro, M.
Schmied, B.
Zangerle, R.
Karpov, I.
Vassilenko, A.
Mitsura, V.M.
Paduto, D.
Clumeck, N.
De Wit, S.
Delforge, M.
Florence, E.
Vandekerckhove, L.
Hadziosmanovic, V.
Begovac, J.
Machala, L.
Sedlacek, D.
Kronborg, G.
Gerstoft, J.
Katzenstein, T.
Pedersen, C.
Johansen, I.S.
Ostergaard, L.
Wiese, L.
Moller, N.F.
Nielsen, L.N.
Zilmer, K.
Smidt, J.
Aho, I.
Lacombe, K.
Pradier, C.
Fontas, E.
Rockstroh, J.
Behrens, G.
Hoffmann, C.
Stellbrink, H.J.
Stefan, C.
Bogner, J.
Fätkenheuer, G.
Chkhartishvili, N.
Sambatakou, H.
Adamis, G.
Paissios, N.
Szlávik, J.
Gottfredsson, M.
Devitt, E.
Tau, L.
Turner, D.
Burke, M.
Shahar, E.
Wattad, L.M.
Elinav, H.
Haouzi, M.
Elbirt, D.
D'Arminio Monforte, A.
Esposito, R.
Mazeu, I.
Mussini, C.
Mazzotta, F.
Gabbuti, A.
Lazzarin, A.
Castagna, A.
Gianotti, N.
Galli, M.
Ridolfo, A.
Uzdaviniene, V.
Matulionyte, R.
Staub, T.
Hemmer, R.
Dragas, S.
Stevanovic, M.
Vd Valk, M.
Trajanovska, J.
Reikvam, D.H.
Maeland, A.
Bruun, J.
Szetela, B.
Inglot, M.
Flisiak, R.
Grzeszczuk, A.
Parczewski, M.
Maciejewska, K.
Aksak-Was, B.
Mularska, E.
Jablonowska, E.
Kamerys, J.
Wojcik, K.
Mozer-Lisewska, I.
Rozplochowski, B.
Mansinho, K.
Radoi, R.
Oprea, C.
Gusev, D.
Trofimova, T.
Khromova, I.
Borodulina, E.
Ranin, J.
Tomazic, J.
Miró, J.M.
Laguno, M.
Martinez, E.
Garcia, F.
Blanco, J.L.
Martinez-Rebollar, M.
Mallolas, J.
Callau, P.
Rojas, J.
Inciarta, A.
Moreno, S.
Del Campo, S.
Clotet, B.
Jou, A.
Paredes, R.
Puig, J.
Santos, J.R.
Gutierrez, M.
Mateo, G.
Sambeat, M.A.
Laporte, J.M.
Svedhem, V.
Thalme, A.
Sönnerborg, A.
Brännström, J.
Flamholc, L.
Kusejko, K.
Braun, D.
Calmy, A.
Furrer, H.
Battegay, M.
Schmid, P.
Kuznetsova, A.
Sluzhynska, M.
Johnson, A.M.
Simons, E.
Edwards, S.
Phillips, A.
Johnson, M.A.
Orkin, C.
Winston, A.
Clarke, A.
Leen, C.
Karpov, I.
Losso, M.
Lundgren, J.
Rockstroh, J.
Aho, I.
Rasmussen, L.D.
Svedhem, V.
Pradier, C.
Chkhartishvili, N.
Matulionyte, R.
Oprea, C.
Kowalska, J.D.
Begovac, J.
Miró, J.M.
Guaraldi, G.
Paredes, R.
Paredes, R.
Larsen, J.F.
Bojesen, A.
Neesgaard, B.
Jaschinski, N.
Fursa, O.
Sather, M.
Raben, D.
Hansen, E.V.
Kristensen, D.
Fischer, A.H.
Jensen, S.K.
Elsing, T.W.
Phillips, A.
Reekie, J.
Cozzi-Lepri, A.
Amele, S.
Pelchen-Matthews, A.
Roen, A.
Tusch, E.S.
Bannister, W.
Groupes de travail
EuroSIDA study group
Liens vers les personnes
Liens vers les unités
ISSN
1468-1293
Statut éditorial
Publié
Date de publication
2022-07
Volume
23
Numéro
6
Première page
585
Dernière page/numéro d’article
598
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH).
All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
PID Serval
serval:BIB_7542D67528C1
PMID
Open Access
Oui
Date de création
2021-12-17T16:30:34.181Z
Date de création dans IRIS
2025-05-20T21:25:56Z